TG Therapeutics reports Phase 1 data for azercabtagene zapreleucel in progressive multiple sclerosis

TG Therapeutics reported initial data from its Phase 1 trial of azercabtagene zapreleucel in patients with progressive multiple sclerosis, showing 89% of evaluable participants had stable or improved disability scores at Day 90. The therapy demonstrated an encouraging safety profile in 26 participants, with no dose-limiting toxicities or high-grade CAR T-associated toxicities, including no Grade ≥3 cytokine release syndrome.

Detected & updated continuously · Source: Nebula